跳至主要内容
临床试验/NCT00796159
NCT00796159已完成不适用

A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertension

Pfizer0 个研究点目标入组 1,723 人开始时间: 2007年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Pfizer
入组人数
1,723
主要终点
Safety (Adverse Events)

研究概览

简要总结

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

详细描述

Non Probability Sampling

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and Female patients 18 to 65 y/old
  • Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP
  • Patient with uncontrolled mild to moderate hypertension (SBP>= 140 and <=179 mmHg OR DBP of >=90 and <=109 mmHg)

排除标准

  • Pregnant of Lactating women
  • History of secondary hypertension

研究组 & 干预措施

Olmesartan medoxomil + HCTZ

干预措施: Olmesartan medoxomil (Drug)

结局指标

主要结局

Safety (Adverse Events)

时间窗: 4 weeks

次要结局

  • Blood Pressure(4 weeks)

研究者

发起方
Pfizer
申办方类型
Industry

相似试验